The main goal of our laboratory is the identification and characterization of signal transduction pathways that cause the dysregulation of growth and inhibition of apoptosis that characterize advanced human cancer. Our laboratory is dedicated to understanding the consequences of activation of these pathways and to using this information to develop mechanism-based therapeutic strategies.
Neal Rosen, MD, PhD
Research FocusPharmacologist Neal Rosen focuses on understanding biochemical mechanisms underlying phenotypes caused by tyrosine kinase activation in epithelial tumors and developing new therapeutic strategies.
EducationMD, PhD, Albert Einstein College of Medicine
- Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N. Cancer Cell. 2012 Nov 13;22(5):668-82. doi: 10.1016/j.ccr.2012.10.009.
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.